^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ALETA-001
i
Other names: ALETA-001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Aleta Biotherap
Drug class:
CD20 inhibitor
Related drugs:
4ms
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies (clinicaltrials.gov)
P1/2, N=72, Recruiting, Cancer Research UK | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
ALETA-001
2years
CAR-T engager proteins for the treatment of B cell cancers and acute myeloid leukemia (AACR 2022)
ALETA-001 is a CAR-T Engager protein that contains the CD19 extracellular domain (ECD), an anti-CD20 VHH, and an anti-albumin VHH for half-life extension...Finally, CAR-T Engagers directed to AML antigens were able to bind each antigen individually, and mediated potent toxicity with the addition of CAR19 T cells.We conclude that the CAR-T Engager platform offers robust and modular anti-tumor functionality, featuring potent multi-antigen targeting for diverse indications. Finally, we can incorporate other useful immunomodulatory activities into Engager proteins.
IO biomarker
|
CD19 (CD19 Molecule) • CDR2 (Cerebellar Degeneration Related Protein 2)
|
CD20 positive • CD19 positive • CD19 expression • CD20 negative
|
ALETA-001
Share via
